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Abstract
Background: Urachal carcinoma is a rare malignancy with poor prognosis due to late presentation of the disease
and its aggressiveness. Surgery remains the mainstay of therapy even in cases of disease recurrence. To the best
of our knowledge, this is the first report of salvage surgery in the case of urachal carcinoma with liver metastasis.
Case presentation: The patient was a young woman who suffered from locally advanced urachal carcinoma
treated with en-bloc cystectomy, hysterectomy with bilateral adnexectomy, partial resection of the sigmoid colon,
and partial resection of the rectus abdominis muscle with the fascia, skin, and umbilicus. Adjuvant chemotherapy
with paclitaxel and carboplatin was applied. Two years after the treatment, she was diagnosed with a single liver
metastasis and a local pelvic recurrence. In a two-step operation, the patient underwent right hemihepatectomy
as well as resection of pelvic recurrence site and adjuvant chemotherapy with gemcitabine. Due to the disease
progression, a complete resection of the lesions was not achieved and the response to chemotherapy was poor.
The patient died of the disease after a year.
Conclusions: Surgery is the first line of treatment for urachal carcinoma and should be always considered as an
option in cases of disease recurrence. Radical initial surgical management, close patient surveillance, and prompt
treatment of disease relapse may all contribute to prolonging patient’s survival.
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Background
The urachus is a structure connecting the allantois with
a precursor of the urinary bladder during early embry-
onic development. It involutes before birth into a fibrous
cord extending upward from the anterior dome of the
bladder toward the umbilicus and forming a median um-
bilical ligament. It is a three-layered tubular structure
lying in the Retzius’ space and varying in size from 3 to
10 cm in length and from 8 to 10 mm in diameter [1, 2].
The remnants of urachal tissue in the ligament may be a
source of tumor growth. It is a rare type of malignancy
with incidence below 0.5% of all bladder cancers and the
annual incidence estimated to be 1 in 5 million people
in general population [3, 4]. To date, no specific risk fac-
tors for the development of urachal carcinoma have
been established. In the case of urachal mass of un-
known character, the risk factors of its malignant charac-
ter are age older than 55 years and the presence of
hematuria [5].
The most commonly employed diagnostic criteria for
urachal carcinoma are those proposed by Sheldon et al.
These include (1) tumor in the dome of the bladder, (2)
absence of cystitis cystica and cystitis glandularis, (3)
predominant invasion of the muscularis or deeper tis-
sues with a sharp demarcation between the tumor and
surface bladder urothelium which is free of glandular or
polypoid proliferation, (4) presence of urachal remnants
within the tumor, (5) extension of tumor into the blad-
der wall involving the space of Retzius, anterior abdom-
inal wall, or umbilicus, and (6) no evidence of a primary
neoplasm elsewhere [4]. Simplified MD Anderson
Cancer Center criteria published by Siefker-Radtke et al.
include (1) location in the bladder dome or elsewhere in
the midline of the bladder and (2) sharp demarcation
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between tumor and normal surface epithelium. Support-
ive criteria include enteric-type histology, absence of
urothelial dysplasia, cystitis cystica or cystitis glandularis
transitioning to the tumor, and absence of primary
adenocarcinoma of another organ [6].
The majority of authors follow a staging system for
urachal carcinoma proposed by Sheldon. Recently, a
simplified system developed in Mayo Clinic has been
proven to be of equal value. Table 1 compares both
systems [4, 5].
Following the diagnosis of urachal carcinoma, the first
line treatment consists of partial or radical cystectomy
together with wide surgical excision of remaining ura-
chal ligament, surrounding soft tissue, and umbilicus.
Bilateral pelvic lymphadenectomy is optional [5–8]. As
the cancer is usually diagnosed at an advanced stage, the
incidence of local recurrences or distant metastases
following the treatment is high. Due to the rarity of the
disease, no clinical trials are available to assist in the
choice of further treatment. Several chemotherapy regi-
mens have been tested so far with limited success.
Salvage surgical treatment with adjuvant chemother-
apy in cases of disease relapse has been described in
some studies as potentially prolonging patients’ sur-
vival [5, 9, 10].
Case presentation
A 34-year-old woman with a history of urachal carcin-
oma was referred to our department (Department of
Liver and General Surgery) in January 2015 in order to
surgically treat a disease relapse presenting with a liver
metastasis. The patient was an otherwise healthy
woman. The first symptoms of the disease occurred in
December 2011 and included urinary frequency, dysuria,
and episodic gross hematuria. In January 2012, the pa-
tient sought medical attention. The primary care phys-
ician diagnosed urinary tract infection and ordered
antibiotics. After two months, an abdominal ultrasound
was performed, however with an empty bladder, and the
disease focus was not recognized. It was not until April
2012 that the patient came directly to the emergency
department and was for the first time consulted by a ur-
ologist. At that point, the diagnosis of urinary bladder
tumor was made. A CT scan showed a pathologic mass
in the region of the bladder dome extending toward the
umbilicus (Fig. 1) which is a typical appearance of ura-
chal carcinoma [11]. It was adherent to the sigmoid
colon, and there were signs of the surrounding adipose
tissue and peritoneum involvement. No sites of distant
metastases on abdominal CT scan and chest X-ray were
noted.
In June 2012, the patient underwent radical cystec-
tomy including hysterectomy, bilateral adnexectomy,
partial resection of the sigmoid colon, and partial resec-
tion of the rectus abdominis muscle with the fascia, skin,
and umbilicus. A urinary diversion with a Studer-type
orthotopic ileal neobladder was constructed. Intraopera-
tive histologic examination of two ileal lymph nodes was
negative. However, a post-operative examination of these
lymph nodes revealed one metastatic focus. The full spe-
cimen was described in pathology report as a 22 × 19 ×
17 cm in size, with tumor extending between the uterus
and umbilicus involving the urinary bladder and extend-
ing beyond its wall. On microscopic examination, a
mucous-producing adenocarcinoma consistent with ura-
chal carcinoma was diagnosed. The involvement of the
sigmoid colon was caused by an inflammatory response.
Other resected organs as well as surgical margins were
free of neoplastic infiltration. The patient received four
cycles of adjuvant chemotherapy with paclitaxel and
carboplatin.
A follow-up CT scan performed a year after surgery
(July 2013) showed no signs of disease recurrence. In
November 2014, another CT scan revealed a hypodense
mass in the right liver lobe of max 40 mm in diameter.
A collection of fluid in the region of the right iliac ves-
sels with calcifications was also noted (in a region where
in previous imaging studies a simple lymphocele was
described). A subsequent PET-CT scan of entire body
proved a high probability of disease recurrence in the
liver and in the region of the right iliac vessels (Fig. 2). A
biopsy of the liver mass confirmed a focus of metastatic
disease. After presentation of possible therapeutic op-
tions to the patient, she chose a surgical treatment. The
surgery took place in January 2015. Intraoperative find-
ings with the use of ultrasonography included a tumor
Table 1 Comparison of urachal carcinoma staging systems
Stage Sheldon Mayo clinic
I Confined to the urachal
mucosa
Confined to the urachus and/or
the bladder
II Invasion confined to the
urachus itself
Extension beyond the muscular
layer of the urachus and/or the
bladder
III Metastases to the regional
lymph nodes
IIIA Extension to the bladder
IIIB Extension to the
abdominal wall
IIIC Extension to the peritoneum
IIID Extension to the viscera
other than the bladder
IV Metastases to non-regional
lymph nodes or other distant
sites
IVA Metastases to the lymph
nodes
IVB Metastases to distant sites
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of max 80 mm in diameter in the right liver lobe with a
small satellite focus on the liver phrenic surface. Despite
the probability of local recurrence in the pelvis, a right
hemihepatectomy was performed. This decision was
based on a large tumor size and a possible expansion
into the vena cava inferior and liver hilum (Fig. 3). The
pathology report revealed a metastatic urachal carcin-
oma and a positive surgical margin. Magnetic resonance
imaging performed a month after the surgery confirmed
enlargement of the pathologic mass in the pelvis. No
other sites of the disease were noted. Patient was quali-
fied to a second-stage surgical treatment and underwent
an excision of the tumor mass in the region of the right
iliac vessels in April 2015; however, complete resection
has not been achieved.
Following the surgery, the patient received three cycles
of adjuvant gemcitabine-based chemotherapy. Subse-
quent imaging studies showed gradual disease progres-
sion. The patient died of the disease in March 2016.
Discussion
The presented case illustrates difficulties associated with
the diagnosis and treatment of the urachal carcinoma. It
took over 6 months since the patient started experien-
cing symptoms and sought medical attention until the
treatment was instituted. This significant delay may have
contributed to the advanced stage of the disease found
at the time of the cystectomy. Literature review shows
that the first urachal carcinoma symptoms include most
commonly hematuria, followed by palpable mass in the
lower abdomen, abnormalities in urine sample examin-
ation, and pain [12, 13]. Unfortunately, these occur
mostly late in the course of the disease which leads to
local cancer invasion or metastatic foci often being
present at diagnosis [4]. In the study by Gopalan et al.
among all 24 patients examined, there were no cases of
Sheldon stage I or II tumors [14]. In another
population-based study among 40 patients diagnosed
with urachal tumor, only in one case cancer was con-
fined to the urachus [15].
The pathologic study of urachal carcinoma in the ma-
jority of cases reveals an intestinal type adenocarcinoma
with morphological variants including mucinous, en-
teric, signet ring cell type, and not otherwise specified
(NOS) [16]. In the case of our patient, a mucinous type
adenocarcinoma was found. This type, together with
NOS adenocarcinoma, is the most frequent variant en-
countered [3, 4, 16, 17]. None of these variants, however,
was found to have prognostic value, possibly due to
paucity of patients [3, 14, 16]. In a recent study by
Bisosonnette et al., the authors used a micro-RNA
expression profiling in order to genetically differentiate
between morphologic types of urachal carcinoma. No
significant differences were found suggesting that ura-
chal adenocarcinoma can be viewed as a single biological
entity [18].
Due to the rarity of urachal carcinoma, no evidence-
based standards of treatment have been developed. Wide
Fig. 1 Pelvic CT scan at the time of diagnosis. Tumor mass is demarcated from the contrast-filled bladder (white arrow). a Coronal plane.
b Transverse plane
Fig. 2 Abdominal and pelvic CT scan at the time of disease recurrence. a Liver metastatic focus (white arrow). b Local recurrence in the region of
the right iliac vessels (white arrow)
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surgical excision is widely regarded as the treatment of
choice. A study by Henly et al. found no significant dif-
ferences in the survival rate after radical cystectomy vs.
partial cystectomy [19]. To date, published reports have
not confirmed clear advantages of radical cystectomy
(when partial cystectomy with safe surgical margins is
technically feasible). However, the study by Gopalan
et al. indicates a lower local recurrence rate in cases
without bladder-sparing surgery [14]. In the last decade,
an increasing amount of urachal carcinoma surgical
treatment is performed using minimally invasive laparo-
scopic or robot-assisted technique. Although no studies
have directly compared open surgery with minimally
invasive techniques, the available case reports show that
laparoscopic approach allows for radical surgical exci-
sion with the added benefit of reduced blood loss,
decreased postoperative patient discomfort, and shorter
hospital stay [20–22].
Another issue not standardized due to a low number
of urachal carcinoma cases is the need to perform pelvic
lymph node dissection (PLND). In the case of our
patient, PLND was not performed. Intraoperative assess-
ment of two lymph nodes brought a false negative result.
To date, evidence is lacking to support performing
PLND in all cases of urachal carcinoma. On the other
hand, available data indicate that local recurrence of ura-
chal carcinoma (including pelvic lymph nodes involve-
ment) is the most frequent presentation of disease
relapse [5, 14]. Moreover, the pelvic lymph nodes,
together with the lungs, are the most frequent site of
urachal carcinoma metastases [12, 14]. Based on avail-
able literature, performing PLND is described as
optional. Some authors advocate sampling the lymph
nodes, while others performing the extended PLND in
all cases [5, 12, 13]. In the majority of recent
descriptions of urachal carcinoma treatment, the PLND
was performed similarly to the case of locally advanced
bladder cancer where it is proved to benefit patients’ sur-
vival [13, 21, 23–25]. In the presented case, PLND could
be of therapeutic value.
After receiving initial surgical treatment and adju-
vant chemotherapy, the patient follow-up scheme
included only abdominal CT scan a year after the
treatment. The next abdominal CT scan, which raised
the suspicion of the disease recurrence, was per-
formed over a year later and, in fact, due to the pa-
tient’s symptoms—leg pain. There are no guidelines
on follow-up scheme after radical cystectomy due to
urachal carcinoma. Standards are adapted from treat-
ment of muscle-invasive urothelial bladder cancer or
aggressive adenocarcinomas. However, even in cases
of these more prevalent diseases, no universally ac-
cepted standards supported by scientific cost-benefit
analysis exist. Nevertheless, recent studies regarding
follow-up schemes after radical cystectomy acknow-
ledge the need for more frequent and multi-modal
surveillance in cases of stage III and IV disease [26].
In cases such as the one described above, it would
seem prudent to schedule abdominal CT scans more
often and include different modalities such as ab-
dominal ultrasonography and chest X-ray into the
scheme.
The chemotherapeutic regimens received by the pa-
tient consisted of paclitaxel and carboplatin combination
and, during the relapse treatment, of gemcitabine. These
regimens have been described in single cases to elicit a
favorable response in the treatment of metastatic urachal
carcinoma [5, 24, 27, 28]. However, no single chemo-
therapy regimen is to date proved effective enough to
be considered a first-choice in all cases. Importantly,
in the setting of salvage treatment, it is surgery that
remains the most effective and potentially curative
method [5]. Adjuvant chemotherapy in the cases of
recurrent disease is usually applied. A multimodal
treatment of metastatic urachal carcinoma has been
shown to be capable of slowing disease progression
and of providing over 10-year disease-free survival (in
single cases) [7, 29, 30].
Our patient’s decision to submit to salvage surgery
presented a major technical challenge. Since the diagno-
sis of liver metastasis until the surgery (a period of
2 months), the tumor grew from 4 to 8 cm and another
metastatic focus in the liver was revealed. During hemi-
hepatectomy, the tumor localization did not allow to ob-
tain surgical margins considered sufficient (more than
1 cm), instead, resection within tumor pseudocapsule
was performed. It is known that even such resection is
potentially curative; however, in our case, the pathology
report confirmed R1 type resection [31].
Fig. 3 The right liver lobe with a metastatic tumor and a
satellite focus
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Conclusions
Urachal carcinoma is an extremely rare and aggressive
malignancy posing a significant diagnostic and thera-
peutic challenge. The surgical management of the dis-
ease remains the cornerstone of therapy. The present
report is the first to describe a salvage surgery in the
case of urachal carcinoma with liver metastasis. It em-
phasizes the need for a prompt diagnosis and surgical
treatment of urachal carcinoma. As is the case with all
urinary bladder tumors, hematuria as an alerting symp-
tom is still too often ignored by both patients and pri-
mary care physicians. What is more, the described case
should bring more attention to the need for performing
pelvic lymph node dissection and the necessity for a
close follow-up surveillance in cases of an advanced
urachal carcinoma.
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